<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>871</ReferenceId>
        <DateLastUpdated>2016-11-03-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15722596</PubmedId>
            <Abstract>Infection of BALB/c mice with murine cytomegalovirus (MCMV) leads to CD8 cell responses to an immunodominant epitope YPHFMPTNL. We presented this epitope as a nasal peptide vaccine in combination with cholera toxin adjuvant, and evaluated immune responses and protection from MCMV challenge. Vaccination of naive mice generated elevated numbers of peptide-specific interferon-gamma-secreting splenocytes (median 80/million, range 60 to 490), compared to control mice (median 2/million, range -4.5 to 8; P=0.008, Mann-Whitney test). Twelve days after challenge with virulent MCMV, vaccinated mice had a 1.1 log(10) reduction in salivary gland viral titer compared to unvaccinated controls (5.36+/-0.24 vs. 6.42+/-0.12, mean +/-SD log(10) plaque-forming-units; P &lt;0.001, t -test). Mice with chronic MCMV infection had consistent responses to the peptide (183+/-24/million interferon-gamma-secreting splenocytes). Nasal peptide vaccination during chronic infection boosted peptide-specific responses in two of four mice to &gt;900/million interferon-gamma-secreting splenocytes. Nasal peptide vaccination was immunogenic in na√Øve and MCMV-infected mice, and reduced viral burden in naive mice after virulent MCMV challenge. The nasal route may be useful for peptide presentation by novel human vaccines.</Abstract>
            <ArticleYear>2005</ArticleYear>
            <ArticlePages>113-9</ArticlePages>
            <ArticleTitle>Nasal peptide vaccination elicits CD8 responses and reduces viral burden after challenge with virulent murine cytomegalovirus.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Gopal</LastName>
                    <ForeName>Indulekha N</ForeName>
                </Author>
                <Author>
                    <LastName>Quinn</LastName>
                    <ForeName>Anita</ForeName>
                </Author>
                <Author>
                    <LastName>Henry</LastName>
                    <ForeName>Stanley C</ForeName>
                </Author>
                <Author>
                    <LastName>Hamilton</LastName>
                    <ForeName>John D</ForeName>
                </Author>
                <Author>
                    <LastName>Staats</LastName>
                    <ForeName>Herman F</ForeName>
                </Author>
                <Author>
                    <LastName>Frothingham</LastName>
                    <ForeName>Richard</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA.</Affiliations>
            <ArticleChemicalList>Adjuvants, Immunologic;Immunodominant Epitopes;Vaccines, Synthetic;Viral Vaccines;Interferon-gamma;Cholera Toxin</ArticleChemicalList>
            <ArticleMeshHeadingsList>Adjuvants, Immunologic(administration &amp; dosage); Administration, Intranasal; Animals; CD8-Positive T-Lymphocytes(immunology); Cholera Toxin(administration &amp; dosage); Herpesviridae Infections(immunology; prevention &amp; control; virology); Immunodominant Epitopes(administration &amp; dosage; immunology); Interferon-gamma(biosynthesis); Lymphocyte Count; Mice; Mice, Inbred BALB C; Muromegalovirus(immunology); Salivary Glands(virology); Spleen(immunology); Vaccination; Vaccines, Synthetic(administration &amp; dosage; immunology); Viral Load; Viral Vaccines(administration &amp; dosage; immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>49</Volume>
                <Issue>2</Issue>
                <Title>Microbiology and immunology</Title>
                <Issn>0385-5600</Issn>
                <MedlineTa>Microbiol Immunol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>YPHFMPTNL</LinearSequence>
                        <StartingPosition>168</StartingPosition>
                        <EndingPosition>176</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P11210.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10367</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 114</LocationOfData>
                <EpitopeId>75317</EpitopeId>
                <ReferenceStartingPosition>168</ReferenceStartingPosition>
                <ReferenceEndingPosition>176</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <TCellId>9564</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>6-8 weeks-old</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo to prevent or reduce disease</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>YPHFMPTNL</LinearSequence>
                                            <StartingPosition>168</StartingPosition>
                                            <EndingPosition>176</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P11210.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>10367</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Cholera toxin</Adjuvant>
                                <Route>Intranasal</Route>
                                <DoseSchedule>Mice were immunized on days 0, 7, and 14.</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Murine cytomegalovirus</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>10367</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>182</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>5</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>5</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>Mice were challenged with intraperitoneal injections of murine cytomegalovirus on day 21 and salivary glands were harvested on day 33 in order to determine vial titers.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <TCellId>9560</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>6-8 weeks-old</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>YPHFMPTNL</LinearSequence>
                                            <StartingPosition>168</StartingPosition>
                                            <EndingPosition>176</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P11210.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>10367</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>Cholera toxin</Adjuvant>
                                <Route>Intranasal</Route>
                                <DoseSchedule>Mice were immunized on days 0, 7, 14, and 28.</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>YPHFMPTNL</LinearSequence>
                                        <StartingPosition>168</StartingPosition>
                                        <EndingPosition>176</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P11210.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10367</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>5</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>5</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 3</LocationOfData>
                        <TCellId>9565</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>6-8 weeks-old</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <DiseaseState>DOID:934</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10367</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Chronically-infected mice were established by infection with murine cytomegalovirus, followed by a 2 month wait before evaluation of splenocytes.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>YPHFMPTNL</LinearSequence>
                                        <StartingPosition>168</StartingPosition>
                                        <EndingPosition>176</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P11210.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10367</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>5</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>5</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>An additional group of four mice received a nasal peptide vaccination boost during the chronic infection and 2 of the 4 were shown to have increased frequencies of peptide-specific IFN-Œ≥ splenocytes.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

